Menu
Recruiting NCT07570472

The Effect of CBD on Sleep Quality Following Late Evening Exercise

Phase II Interventional Sleep Quality

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Cannabidiol or placebo, late evening exercise.
Who it may be relevant to
Registry conditions: Sleep Quality. Basic parameters: 18 years — 40 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Belgium
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The trial is a double-blind, placebo-controlled crossover design. In a randomized order, 20 participants undergo one control and two experimental sessions separated by a 1-week wash out period. During the no exercise/rest session, participants' sleep is monitored via polysomnography following a rest day. During the training sessions participants' sleep is monitored following a high intensity interval training (HIIT) in the late evening (finishing 1h prior to bedtime). During these sessions participants receive 2x 200mg CBD or placebo in a randomized order.

Interventions

  • Drug Cannabidiol or placebo
    participants receive 2 x 200mg CBD or placebo
  • Behavioral late evening exercise
    Participants perform a late evening high-intensity interval training (HIIT) ending 1 hour prior to sleep

Primary outcome measures

  • sleep efficiency [Time frame: Nightly assessment on three specific study nights, separated by 7-day intervals]
Secondary outcome measures (4)
  • Sleep indices (other than sleep efficiency) [Time frame: Nightly assessment on three specific study nights, separated by 7-day intervals]
  • Perceived sleep quality [Time frame: Assessment on three specific study mornings, separated by 7-day intervals]
  • Circulating hormones involved in sleep and stress [Time frame: Assessment on three specific study nights, separated by 7-day intervals]
  • Plasma and urinary catecholamines (adrenaline, noradrenaline, dopamine) and serotonin concentration [Time frame: Assessment on three specific study nights, separated by 7-day intervals]

Eligibility criteria

Inclusion criteria

  • Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
  • Use of highly effective methods of birth control during the entire trial and for up to 4 months after the last dose of CBD; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner.
  • Age between 18-40 years old at the time of signing the Informed Consent Form (ICF)
  • Recreationally active (between 2-8h/wk)
  • Good health status confirmed by a sport medical screening
  • Body fat percentage below 20% (males) or 25% (females) as estimated by a Dual-energy X-ray absorptiometry (DXA) scan
  • Good sleep efficiency determined by the Pittsburgh Sleep Quality Index (PSQI, score ≤ 4)

Exclusion criteria

  • Self-reported sleep disturbances
  • Habitual smoking (> 1 occasion/month)
  • Any kind of injury/incapability that is a contra-indication to perform high intensity interval training
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
  • Participation in another interventional Trial with an investigational medicinal product (IMP) or device
  • Use of CBD related products 3 months prior to the start of the experimental trial (including CBD oil, cannabis or other substances containing cannabinoids)
  • Intake of any medication or nutritional supplement that influences sleep quality 3 months prior to the start of the experimental trial
  • Shift workers or extreme morning and evening chronotypes (scores between 16-30 or 70-86 on the Morningness-Eveningness Questionnaire (MEQ))

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

Belgium · 1 center
  • Bakala Athletic Performance Facility — Leuven

Identifiers

NCT: NCT07570472 · S69706 · 2024-518609-17-00

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗